MB07811

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 466215

CAS#: 852948-13-1 (2R4S)

Description: MB07811, also known as VK2809, is an orally bioavailable, liver-targeted prodrug of MB07344, which is a thyroid hormone receptor-beta agonist (TRβ) agonist, efficiently converted to MB07344 by liver microsomes in vivo. MB07811 lowers Plasma Cholesterol in Cynomolgus Monkeys as Effectively as Atorvastatin. MB07811 demonstrates promising cholesterol lowering activity without inducing tachycardia or other side effects in cynomolgus monkeys.


Chemical Structure

img
MB07811
CAS# 852948-13-1 (2R4S)

Theoretical Analysis

MedKoo Cat#: 466215
Name: MB07811
CAS#: 852948-13-1 (2R4S)
Chemical Formula: C28H32ClO5P
Exact Mass: 514.17
Molecular Weight: 514.980
Elemental Analysis: C, 65.30; H, 6.26; Cl, 6.88; O, 15.53; P, 6.01

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 916055-16-8 (racemate)   852948-13-1 (2R4S)   915233-90-8 (2S4R)    

Synonym: MB-07811; MB07811; MB 07811; VK2809; VK-2809; VK 2809;

IUPAC/Chemical Name: Phenol, 4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-(1-methylethyl)-

InChi Key: LGGPZDRLTDGYSQ-JADSYQMUSA-N

InChi Code: InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1

SMILES Code: OC1=CC=C(CC2=C(C)C=C(OC[P@]3(OCC[C@@H](C4=CC=CC(Cl)=C4)O3)=O)C=C2C)C=C1C(C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 514.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Luong XG, Stevens SK, Jekle A, Lin TI, Gupta K, Misner D, Chanda S, Mukherjee S, Williams C, Stoycheva A, Blatt LM, Beigelman LN, Symons JA, Raboisson P, McGowan D, Vandyck K, Deval J. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non- alcoholic steatohepatitis (NASH). PLoS One. 2020 Dec 11;15(12):e0240338. doi: 10.1371/journal.pone.0240338. PMID: 33306682; PMCID: PMC7732128.

2: Zhou J, Waskowicz LR, Lim A, Liao XH, Lian B, Masamune H, Refetoff S, Tran B, Koeberl DD, Yen PM. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia. Thyroid. 2019 Aug;29(8):1158-1167. doi: 10.1089/thy.2019.0007. PMID: 31337282; PMCID: PMC6707038.

3: Mondal S, Mugesh G. Novel thyroid hormone analogues, enzyme inhibitors and mimetics, and their action. Mol Cell Endocrinol. 2017 Dec 15;458:91-104. doi: 10.1016/j.mce.2017.04.006. Epub 2017 Apr 11. PMID: 28408161.

4: Tancevski I, Eller P, Patsch JR, Ritsch A. The resurgence of thyromimetics as lipid-modifying agents. Curr Opin Investig Drugs. 2009 Sep;10(9):912-8. PMID: 19705333; PMCID: PMC2993058.

5: Ito BR, Zhang BH, Cable EE, Song X, Fujitaki JM, MacKenna DA, Wilker CE, Chi B, van Poelje PD, Linemeyer DL, Erion MD. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol. 2009 Feb;156(3):454-65. doi: 10.1111/j.1750-3639.2009.00038.x. Epub 2009 Jan 22. PMID: 19183199; PMCID: PMC2697679.

6: Boyer SH, Jiang H, Jacintho JD, Reddy MV, Li H, Li W, Godwin JL, Schulz WG, Cable EE, Hou J, Wu R, Fujitaki JM, Hecker SJ, Erion MD. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J Med Chem. 2008 Nov 27;51(22):7075-93. doi: 10.1021/jm800824d. PMID: 18975928.

7: Fujitaki JM, Cable EE, Ito BR, Zhang BH, Hou J, Yang C, Bullough DA, Ferrero JL, van Poelje PD, Linemeyer DL, Erion MD. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos. 2008 Nov;36(11):2393-403. doi: 10.1124/dmd.108.021642. Epub 2008 Aug 14. PMID: 18703645.